Letter to the EditorThe impacts of dopamine D2 receptor polymorphism and antipsychotic dosage on dopamine supersensitivity psychosis in schizophrenia
Section snippets
Contributors
Study concept and design: Kanahara, Iyo.
Acquisition of data: Takase, Oda, Kanahara.
DNA analysis and interpretation of data: Takase, Oda, Niitsu, Kanahara.
Drafting of the manuscript: Takase, Kanahara, Iyo.
Obtained funding: Kanahara.
Study supervision: Watanabe, Iyo.
Conflict of interests
Dr. Takase reports honoraria from Otsuka. Dr. Kanahara received grant funding from the Ministry of Health, Labour and Welfare of Japan and the SENSHIN Medical Research Foundation and reports honoraria from Eli Lilly, Otsuka, Sumitomo Dainippon, Meiji Seika and Janssen. Dr. Niitsu reports speaker's honoraria from Eli Lilly, Meiji Seika Pharma, Mochida and Sumitomo Dainippon. Dr. Watanabe reports honoraria from Eli Lilly, Sumitomo Dainippon, Astellas, GlaxoSmithKline, Mochida and Eisai. Dr. Iyo
Role of the funding source
This study was supported by Grant-in-Aid for Young Scientists (B) from Japan Society for the Promotion of Science (JSPS) (Grant no. 25860989).
Acknowledgement
The authors thank Ms. M. Nakamura for her technical assistance.
References (8)
Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment
Schizophr. Res.
(1991)- et al.
Impact of dopamine supersensitivity psychosis in treatment-resistant schizophrenia: an analysis of multi-factors predicting long-term prognosis
Schizophr. Res.
(2016) - et al.
Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis
J. Clin. Psychopharmacol.
(2013) - et al.
Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers
Mol. Psychiatry
(1999)
Cited by (4)
Association of Genetic Variants of Dopamine and Serotonin Receptors with Schizophrenia
2020, Archives of Medical ResearchCitation Excerpt :Later with bigger sample size and additional polymorphisms enrolled they showed no association of Taq1A and HTR2A ‒1438 G/A, 102T/C and HTR2C ‒759 C/T with antipsychotic response to risperidone (44). For the same polymorphism Takase M, et al. (2017) has recently found a relationship between Del carriers and high-dose pharmacotherapy in schizophrenia (45). Previously, a rs1076560 regulatory polymorphism of the DRD2 gene has been identified as a genetic risk factor for schizophrenia and has been involved in schizophrenia intermediate phenotypes in the meta-analysis (46).
Genetic risks of schizophrenia identified in a matched case–control study
2021, European Archives of Psychiatry and Clinical NeuroscienceMetabolism of risperidone by CYP2D6 and the presence of drug-induced dopamine supersensitivity psychosis in patients with schizophrenia
2019, International Clinical Psychopharmacology